33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Assessment of oncofertility content on reproductive endocrinology and infertility clinic websites
    Meeting Abstract

    Mujumdar, V.; Shivashankar, K.; Madding, R.; Levy, A.; Richard, S.; Gordhandas, S.; Rosenblum, N.; Monseur, B.
    Gynecologic Oncology (2021)

    Fulltext@MSK | Save
  • Breast nodule in a male-to-female transgender (MFT) adolescent
    Meeting Abstract

    Essoh, S.; Kallakuri, A.; Heerdt, A.; Ten, S.
    Hormone Research in Paediatrics (2021)

    Fulltext@MSK | Save
  • TERT promoter mutations associated with longer progression-free and overall survival under BRAF/MEK therapy
    Meeting Abstract

    Thielmann, C. M.; Matull, J.; Zaremba, A.; Murali, R.; Chorti, E.; Lodde, G.; Jansen, P.; Herbst, R.; Terheyden, P.; Utikal, J. S.; more...
    Journal Der Deutschen Dermatologischen Gesellschaft (2021)

    Fulltext@MSK | Save
  • Morphological subtyping of breast cancer using machine learning
    Meeting Abstract

    Hanna, M.; Lee, M.; Bozkurt, A.; Hamilton, P.; Godrich, R.; Casson, A.; Raciti, P.; Sue, J.; Viret, J.; Lee, D.; more...
    Journal of Pathology (2021)

    Fulltext@MSK | Save
  • Belantamab mafodotin (belamaf; GSK2857916) US expanded access program (EAP) for heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM): Baseline characteristics
    Meeting Abstract

    Hultcrantz, M.; Anderson, L. D. Jr; Anwer, F.; Gasparetto, C.; Kocoglu, M. H.; Lichtman, E. I.; Mo, C.; Niesvizky, R.; Lewis, E.; Li, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • MagnetisMM-1: A study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-targeted, CD3-engaging bispecific antibody, for patients with relapsed or refractory multiple myeloma (MM)
    Meeting Abstract

    Levy, M.; Bahlis, N.; Raje, N.; Costello, C.; Dholaria, B.; Solh, M.; Tomasson, M.; Dube, H.; Damore, M.; Lon, H. K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • A tumor-agnostic TCR-mimic CAR-T cell specific for NDC80 targets multiple hematological malignancies
    Meeting Abstract

    Klatt, M. G.; Dao, T.; Yang, Z.; Liu, J.; Mun, S. S.; Dacek, M. M.; Luo, H.; Gardner, T. J.; Bourne, C.; Peraro, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Incidence, mitigation, and management of neurologic adverse events in the CARTITUDE-2 study of patients with multiple myeloma treated with ciltacabtagene autoleucel (cilta-cel)
    Meeting Abstract

    Jakubowiak, A.; Parekh, S.; Madduri, D.; Santomasso, B.; Perez-Larraya, J. G.; van de Donk, N. W. C. J.; Arnulf, B.; Mateos, M. V.; De Braganca, K. C.; Varsos, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Melflufen plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) exposed or refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies
    Meeting Abstract

    Rodriguez-Otero, P.; Mateos, M. V.; Oriol, A.; Larocca, A.; Blade, J.; Cavo, M.; Leleu, X.; Nadeem, O.; Hiemenz, J. W.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone in 55 patients with relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD): Subgroup analysis
    Meeting Abstract

    Richardson, P. G.; Mateos, M. V.; Oriol, A.; Larocca, A.; Cavo, M.; Rodríguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save